Clinical trials: Age
Cystic Fibrosis
A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)
This study will evaluate the effects of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) on cough and physical activity using wearable technology in CF participants.
- Trial name
- NCT04969224
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 19 sites in Australia, Belgium and 2 more
- Volunteers
- 82 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Blast Injuries, Brain Injuries
Central Auditory Processing Deficits Associated With Blast Exposure
The current conflicts in Afghanistan and Iraq have resulted in unprecedented rates of exposure to high-intensity blasts and resulting brain injury.
- Conditions
- Blast Injuries, Brain Injuries, Age Factors
- Trial name
- NCT01567020
- Testing
- Diagnostic
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Chronic Low Back Pain, Hip Ostearthritis
Making Better Lives: Patient-Focused Care for Low Back Pain (LBP)
Back pain is a huge problem for millions of Americans, including nearly 11 million Veterans. Our older Veterans suffer the most. Citizens spend billions of dollars, yet consistently get poor results.
- Conditions
- Chronic Low Back Pain, Hip Ostearthritis, Myofascial Pain Syndrome, Fibromyalgia
- Trial name
- NCT02697435
- Testing
- Patient-Centered Care, Imaging-Directed Care
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- VA Office of Research and Development
Influenza
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
The purpose of this study is to evaluate the immunogenicity and the safety of GlaxoSmithKline (GSK) Biologicals' investigational quadrivalent split virion influenza vaccine FLU-Q-QIV in adults 18 years of age and older.
- Trial name
- NCT01440387
- Testing
- FLULAVAL® QUADRIVALENT
- Where
- Canada
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India
The aim of the study was to generate immunogenicity and safety data in the whole population to support registration of the Quadrivalent Influenza Vaccine (QIV) in India: Primary objective: To describe in each age group the immune…
- Trial name
- NCT02451358
- Testing
- Quadrivalent Inactivated Influenza Vaccine (2016-2017 NH formulation), No Preservative, Quadrivalent Inactivated Influenza Vaccine (2016 SH formulation), No Preservative, Quadrivalent Inactivated Influenza Vaccine (2015-2016 NH formulation), No Preservative
- Where
- 8 sites in India
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Loneliness, Quality of Life
The Helping Older People Engage Project: Improving Social Well-Being in Later Life
Older adults who feel lonely carry increased risk for reduced quality of life, morbidity, and mortality. Volunteering is a promising intervention for reducing loneliness in later life.
- Trial name
- HOPE (NCT03343483)
- Testing
- Volunteering, Life Review
- Where
- United States
- Volunteers
- 291 people
- Sponsor
- University of Rochester
Cystic Fibrosis
Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation
This study evaluated the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR)…
- Trial name
- NCT05274269
- Testing
- ELX/TEZ/IVA, IVA
- Where
- 90 sites in Austria, Belgium and 13 more
- Volunteers
- 307 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Exudative Macular Degeneration
Wet Macular Degeneration Study to Compare Ranibizumab or Bevacizumab to Aflibercept
This study will examine the use of Aflibercept in patients with exudative macular degeneration requiring intravitreal injections. Patients will be followed for 24 months. The follow up phase will be completed at month 36.
- Trial name
- NCT01617148
- Testing
- Aflibercept
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Rishi Singh
Age-related Macular Degeneration
Global Atrophie Biomarker Evaluation Study (GABiE)
To investigate the use of microperimetry and SS-OCT in assessing the natural changes of retinal sensitivity and anatomy in the perilesional zone of geographic atrophy areas in patients with dry age-related macular degeneration.
- Trial name
- GABiE (NCT03935126)
- Testing
- Diagnostics
- Where
- 2 sites in United States, Switzerland
- Volunteers
- 3 people
- Sponsor
- Boehringer Ingelheim
Substance Use, Parenting
Feasibility Study of a Web-based Program to Help Parents of Middle School Students Effectively Communicate With Their Children About Substance Use
The goal of this study is to test the feasibility of a web-based program for parents of middle school aged students. 286 parents and their child in 6th, 7th, or 8th grade will be asked to each complete two online questionnaires…
- Conditions
- Substance Use, Parenting, Communication
- Trial name
- NCT05900115
- Testing
- Media Ready Parent, Active Control Program
- Where
- United States
- Volunteers
- 576 people, healthy volunteers welcome
- Sponsor
- Innovation Research & Training
HIV Infections, Sexually Transmitted Diseases
Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children
The purpose of this study is to determine the safety of and immune response to a new human papillomavirus (HPV) vaccine in HIV (Human immunodeficiency virus) infected children between the ages of 7 and 12 years.
- Trial name
- NCT00339040
- Testing
- Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)
- Where
- 34 sites in United States, Puerto Rico
- Volunteers
- 130 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis, Meningococcal Disease
Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea
The aim of the study is to assess safety and immunogenicity of a single dose of Menactra® in support of registration of the vaccine in South Korea.
- Trial name
- NCT01642589
- Testing
- Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed
- Where
- 7 sites in South Korea
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Cardiovascular Diseases in Old Age
Yoga in Older Cardiac Patients
The goal of this clinical trial is to compare, at 3 months, the effects of a yoga intervention on physical health, including balance, muscle strength, physical activity levels, cardiac autonomic function, and physical…
- Trial name
- NCT06235658
- Testing
- Gentle Yoga
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Geunyeong Cha
Crohn's Disease
Safety Study of Entocort for Children With Crohn's Disease
A Safety Study using Entocort EC for children with mild to moderate Crohn's Disease
- Trial name
- NCT01444092
- Testing
- Entocort
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 123 people
- Sponsor
- Padagis LLC
Macular Degeneration, Age-Related, Geographic Atrophy
A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
This study will evaluate the safety, tolerability, and efficacy of intravitreal injections of galegenimab (FHTR2163) administered every 4 weeks (Q4W) or every 8 weeks (Q8W) for approximately 76 weeks in participants with…
- Trial name
- GALLEGO (NCT03972709)
- Testing
- Galegenimab
- Where
- 72 sites in United States
- Volunteers
- 372 people
- Sponsor
- Genentech, Inc.
Infections, Meningococcal
Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612
This study will demonstrate the non-inferiority of GSK Biologicals' meningococcal vaccine 134612 when given in an experimental co-administration versus vaccine 134612 alone and versus the experimental co-administration alone in…
- Trial name
- NCT00465816
- Testing
- Nimenrix (Meningococcal vaccine 134612), Twinrix
- Where
- 6 sites in Denmark, Sweden
- Volunteers
- 611 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Respiratory Syncytial Virus Infections
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
The purpose of this study is to evaluate the clinical lot-to-lot consistency of the respiratory syncytial virus (RSV) maternal (RSV MAT) vaccine administered to healthy non-pregnant women 18-49 years of age (YOA).
- Trial name
- NCT05045144
- Testing
- RSVPreF3(120 μg), Flu Quadrivalent influenza vaccine (15 μg HA)
- Where
- 36 sites in United States, Canada and 3 more
- Volunteers
- 1,586 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of Flublok Quadrivalent vs IIV4 in Adults 18-49 Years of Age
Randomized, double-blind trial of safety and immunogenicity of Flublok Quadrivalent versus Inactivated Influenza Vaccine (IIV4) in 1350 healthy, medically stable adults 18-49 years of age.
- Trial name
- NCT02290509
- Testing
- Flublok Quadrivalent, Inactivated Influenza Vaccine (IIV4)
- Where
- 10 sites in United States
- Volunteers
- 1,350 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
2009 H1N1 Influenza Virus
Effects of Age on Response to the 2009 H1N1 Virus Vaccine
Unlike most influenza viruses, the 2009 H1N1 virus has affected people between 5 and 40 years old more often than people 60 years old or older.
- Trial name
- NCT01055184
- Testing
- 2009 H1N1 Virus Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Multiple Sclerosis, Relapsing-Remitting
Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
The main objective of the study is to evaluate the efficacy of dimethyl fumarate (Tecfidera) and peginterferon beta-1a (Plegridy), both compared with placebo, in pediatric participants with RRMS.
- Trial name
- NCT03870763
- Testing
- Dimethyl Fumarate, Peginterferon Beta-1a
- Where
- 23 sites in United States, Colombia and 11 more
- Volunteers
- 11 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.